Agios says Phase 3 RISE UP trial shows mitapivat boosts hemoglobin response in sickle cell disease patients

Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc.

AGIO

0.00
  • Agios presented detailed 52-week, double-blind Phase 3 RISE UP results for mitapivat in sickle cell disease at EHA 2026.
  • The trial showed a clear improvement in anemia versus placebo, supporting mitapivat’s anti-hemolytic profile with rapid, durable effects.
  • New analyses indicated fewer patients needed transfusions on mitapivat, with lower overall transfusion use than placebo.
  • Patients who achieved a hemoglobin response reported meaningful benefits in pain crises, fatigue, and broader quality-of-life measures versus non-responders.
  • Safety was broadly comparable to placebo, reinforcing a tolerability profile consistent with prior sickle cell studies.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agios Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606130900PRIMZONEFULLFEED9746450) on June 13, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.